Kos, Mitja

Link to this page

Authority KeyName Variants
orcid::0000-0002-1143-1805
  • Kos, Mitja (3)
Projects

Author's Bibliography

Economic burden of cardiovascular diseases in Serbia

Lakić, Dragana; Tasić, Ljiljana; Kos, Mitja

(Vojnomedicinska akademija - Institut za naučne informacije, Beograd, 2014)

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Kos, Mitja
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2264
AB  - Background/Aim. Cardiovascular disease imposes a burden to society in terms of mortality, morbidity and economic losses. The aim of this study was to estimate the economic burden of cardiovascular disease in Serbia in 2009 from the perspective of the society. Methods. For the purpose of the study cardiovascular disease was defined by the International Classification of Diseases, 10th revision, as the following diagnosis: hypertension, coronary heart disease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Productivity losses were estimated using the human capital approach and the friction cost method. A discount rate of 5% was used to convert all future lifetime earnings into the present value. Results. The total direct costs of cardiovascular disease in 2009 were € 400 million. The results showed that more than half a million working days were lost due to incapacity resulting from cardiovascular diseases, yielding the € 113.9 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care - surgical and diagnostic interventions (17.84%). The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. Conclusions. The total cardiovascular disease costs in 2009 represented approximately 1.8% of the Serbian gross domestic product. The results of the study would be valuable to health policy makers to bridge the gap between invested resources and needs, in order to improve cardiovascular disease outcomes.
AB  - Uvod/Cilj. Kardiovaskularne bolesti predstavljaju teret za društvo u smislu mortaliteta, morbiditeta i ekonomskih gubitaka. Cilj ove studije bio je procena ekonomskog značaja kardiovaskularnih bolesti u Srbiji u 2009. godini iz perspektive društva. Metode. Za potrebe istraživanja, kardiovaskularne bolesti su definisane pomoću Međunarodne klasifikacije bolesti, 10. revizija, kao sledeće dijagnoze: hipertenzija, koronarne bolesti, kardiomiopatija, srčana insuficijencija i cerebrovaskularne bolesti. Korišćen je top-down metod, baziran na prevalenciji, kako bi se kvantifikovali godišnji kardiovaskularni troškovi. Troškovi smanjene produktivnosti su procenjeni korišćenjem dva pristupa: pristup ljudskom kapitalu (human capital approach) i metod frikcionih troškova (friction cost method). Za obračunavanje troškova u sadašnju vrednost korišćena je diskontna stopa od 5%. Rezultati. Ukupni direktni troškovi kardiovaskularnih bolesti u 2009. godini iznosili su 400 miliona evra. Rezultati pokazuju da je više od pola miliona radnih dana izgubljeno zbog nesposobnosti usled kardiovaskularnih bolesti, dajući ukupno 113,9 miliona evra indirektne troškove. Većina ukupnih troškova (514,3 miliona evra) bili su za: lekove (29,94%), hospitalizaciju (28,97%) i bolničko lečenje - hirurške intervencije i dijagnostiku (17,84%). Rezultati su bili robusni na promene od 20% u volumenu ili ceni pojedinih kategorija troškova, kao i na primenjenu diskontnu stopu od 2% i od 10%. Zaključak. Ukupni troškovi kardiovaskularnih bolesti u 2009. godini su predstavljali oko 1,8% bruto domaćeg proizvoda. Rezultati studije su značajni za kreiranje zdravstvene politike i premošćavanja jaza između uloženih sredstava i potreba, a u cilju poboljšanja ishoda kardiovaskularnih bolesti.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Economic burden of cardiovascular diseases in Serbia
T1  - Kardiovaskularne bolesti u Srbiji - ekonomski teret
VL  - 71
IS  - 2
SP  - 137
EP  - 143
DO  - 10.2298/VSP1402137L
ER  - 
@article{
author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja",
year = "2014",
abstract = "Background/Aim. Cardiovascular disease imposes a burden to society in terms of mortality, morbidity and economic losses. The aim of this study was to estimate the economic burden of cardiovascular disease in Serbia in 2009 from the perspective of the society. Methods. For the purpose of the study cardiovascular disease was defined by the International Classification of Diseases, 10th revision, as the following diagnosis: hypertension, coronary heart disease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Productivity losses were estimated using the human capital approach and the friction cost method. A discount rate of 5% was used to convert all future lifetime earnings into the present value. Results. The total direct costs of cardiovascular disease in 2009 were € 400 million. The results showed that more than half a million working days were lost due to incapacity resulting from cardiovascular diseases, yielding the € 113.9 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care - surgical and diagnostic interventions (17.84%). The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. Conclusions. The total cardiovascular disease costs in 2009 represented approximately 1.8% of the Serbian gross domestic product. The results of the study would be valuable to health policy makers to bridge the gap between invested resources and needs, in order to improve cardiovascular disease outcomes., Uvod/Cilj. Kardiovaskularne bolesti predstavljaju teret za društvo u smislu mortaliteta, morbiditeta i ekonomskih gubitaka. Cilj ove studije bio je procena ekonomskog značaja kardiovaskularnih bolesti u Srbiji u 2009. godini iz perspektive društva. Metode. Za potrebe istraživanja, kardiovaskularne bolesti su definisane pomoću Međunarodne klasifikacije bolesti, 10. revizija, kao sledeće dijagnoze: hipertenzija, koronarne bolesti, kardiomiopatija, srčana insuficijencija i cerebrovaskularne bolesti. Korišćen je top-down metod, baziran na prevalenciji, kako bi se kvantifikovali godišnji kardiovaskularni troškovi. Troškovi smanjene produktivnosti su procenjeni korišćenjem dva pristupa: pristup ljudskom kapitalu (human capital approach) i metod frikcionih troškova (friction cost method). Za obračunavanje troškova u sadašnju vrednost korišćena je diskontna stopa od 5%. Rezultati. Ukupni direktni troškovi kardiovaskularnih bolesti u 2009. godini iznosili su 400 miliona evra. Rezultati pokazuju da je više od pola miliona radnih dana izgubljeno zbog nesposobnosti usled kardiovaskularnih bolesti, dajući ukupno 113,9 miliona evra indirektne troškove. Većina ukupnih troškova (514,3 miliona evra) bili su za: lekove (29,94%), hospitalizaciju (28,97%) i bolničko lečenje - hirurške intervencije i dijagnostiku (17,84%). Rezultati su bili robusni na promene od 20% u volumenu ili ceni pojedinih kategorija troškova, kao i na primenjenu diskontnu stopu od 2% i od 10%. Zaključak. Ukupni troškovi kardiovaskularnih bolesti u 2009. godini su predstavljali oko 1,8% bruto domaćeg proizvoda. Rezultati studije su značajni za kreiranje zdravstvene politike i premošćavanja jaza između uloženih sredstava i potreba, a u cilju poboljšanja ishoda kardiovaskularnih bolesti.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Economic burden of cardiovascular diseases in Serbia, Kardiovaskularne bolesti u Srbiji - ekonomski teret",
volume = "71",
number = "2",
pages = "137-143",
doi = "10.2298/VSP1402137L"
}
Lakić, D., Tasić, L.,& Kos, M.. (2014). Economic burden of cardiovascular diseases in Serbia. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 71(2), 137-143.
https://doi.org/10.2298/VSP1402137L
Lakić D, Tasić L, Kos M. Economic burden of cardiovascular diseases in Serbia. in Vojnosanitetski pregled. 2014;71(2):137-143.
doi:10.2298/VSP1402137L .
Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, "Economic burden of cardiovascular diseases in Serbia" in Vojnosanitetski pregled, 71, no. 2 (2014):137-143,
https://doi.org/10.2298/VSP1402137L . .
19
13
20

Cost of cardiovascular diseases in Serbia

Lakić, Dragana; Tasić, Ljiljana; Kos, Mitja; Odalović, Marina; Tadić, Ivana

(Elsevier Inc., 2012)

TY  - CONF
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Kos, Mitja
AU  - Odalović, Marina
AU  - Tadić, Ivana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1684
AB  - OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in  20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Cost of cardiovascular diseases in Serbia
VL  - 15
IS  - 7
SP  - A367
EP  - A367
DO  - 10.1016/j.jval.2012.08.974
ER  - 
@conference{
author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja and Odalović, Marina and Tadić, Ivana",
year = "2012",
abstract = "OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in  20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Cost of cardiovascular diseases in Serbia",
volume = "15",
number = "7",
pages = "A367-A367",
doi = "10.1016/j.jval.2012.08.974"
}
Lakić, D., Tasić, L., Kos, M., Odalović, M.,& Tadić, I.. (2012). Cost of cardiovascular diseases in Serbia. in Value in Health
Elsevier Inc.., 15(7), A367-A367.
https://doi.org/10.1016/j.jval.2012.08.974
Lakić D, Tasić L, Kos M, Odalović M, Tadić I. Cost of cardiovascular diseases in Serbia. in Value in Health. 2012;15(7):A367-A367.
doi:10.1016/j.jval.2012.08.974 .
Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, Odalović, Marina, Tadić, Ivana, "Cost of cardiovascular diseases in Serbia" in Value in Health, 15, no. 7 (2012):A367-A367,
https://doi.org/10.1016/j.jval.2012.08.974 . .

Zdravstveni ishodi i socijalna farmacija

Kos, Mitja; Janežić, Ana; Tasić, Ljiljana; Tadić, Ivana

(Beograd: Farmaceutski fakultet Univerziteta u Beogradu, 2012)

TY  - CONF
AU  - Kos, Mitja
AU  - Janežić, Ana
AU  - Tasić, Ljiljana
AU  - Tadić, Ivana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4217
PB  - Beograd: Farmaceutski fakultet Univerziteta u Beogradu
C3  - Zbornik radova simpozijuma "Zdravstveni ishodi & Socijalna farmacija"
T1  - Zdravstveni ishodi i socijalna farmacija
T1  - Health Outcomes and Social Pharmacy
SP  - 18
EP  - 23
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4217
ER  - 
@conference{
author = "Kos, Mitja and Janežić, Ana and Tasić, Ljiljana and Tadić, Ivana",
year = "2012",
publisher = "Beograd: Farmaceutski fakultet Univerziteta u Beogradu",
journal = "Zbornik radova simpozijuma "Zdravstveni ishodi & Socijalna farmacija"",
title = "Zdravstveni ishodi i socijalna farmacija, Health Outcomes and Social Pharmacy",
pages = "18-23",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4217"
}
Kos, M., Janežić, A., Tasić, L.,& Tadić, I.. (2012). Zdravstveni ishodi i socijalna farmacija. in Zbornik radova simpozijuma "Zdravstveni ishodi & Socijalna farmacija"
Beograd: Farmaceutski fakultet Univerziteta u Beogradu., 18-23.
https://hdl.handle.net/21.15107/rcub_farfar_4217
Kos M, Janežić A, Tasić L, Tadić I. Zdravstveni ishodi i socijalna farmacija. in Zbornik radova simpozijuma "Zdravstveni ishodi & Socijalna farmacija". 2012;:18-23.
https://hdl.handle.net/21.15107/rcub_farfar_4217 .
Kos, Mitja, Janežić, Ana, Tasić, Ljiljana, Tadić, Ivana, "Zdravstveni ishodi i socijalna farmacija" in Zbornik radova simpozijuma "Zdravstveni ishodi & Socijalna farmacija" (2012):18-23,
https://hdl.handle.net/21.15107/rcub_farfar_4217 .